Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-07-06 17:10:32 ET · period of report 2026-06-30 · accession 0002001011-26-000106 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 17:10 | 2026-06-30 | LGND | Davis Todd C | CEO, Dir | J - Other | $160.71 | +132 | 199.5K | +0.1% | +$21.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | J | A | 132 | $160.71 | 199,513 | D | — | — | (F1) These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |